Incorporating pharmacogenomic (PGx) information into an institutional formulary can be a daunting task because few standardized methods exist, making the analysis of clinical PGx data at the formulary level particularly difficult. Researchers at the University of North Carolina conducted a Medline search for articles that used terms such as “formularies, hospital,” and “pharmacogenetics.” This yielded no results. The terms were then searched separately, with the additional terms “rational drug therapy” and “essential medicines list.” Results were published in the Annals of Pharmacotherapy.

Mary W. Roederer, PharmD, research assistant professor at the Institute for Pharmacogenomics and Individualized Therapy at the University of North Carolina Eshelman School of Pharmacy in Chapel Hill and one of the authors, says all health systems and managed care organizations have a process for making formulary decisions, but she hopes her article will prompt decision makers to always consider PGx issues. Are there any PGx data? Are there polymorphisms or genes that are relevant to how the drug is metabolized or transported? Are there genes that affect the drug target?

She says many people who evaluate medications are very competent clinicians, but they can be intimidated by the concept of PGx. In addition, a lot of people say the field of PGx is not ready for prime time. But while the field is relatively young, decision makers need to at least consider it and use it to help make decisions. “Pharmacogenomics is just one more piece of the puzzle when deciding what therapies to include in the formulary,” she says. Roederer hopes these questions elicit thought-provoking conversation when decision makers are considering therapies where clinically useful PGx information exists while completing the objective risk-benefit analysis of a traditional P&T committee.

Questions to ask when considering PGx information
Type of question Question
Efficacy What added value does the PGx information provide in regard to individualizing patient care?
Efficacy and safety Does an opportunity exist for patients to utilize a PGx diagnostic test that will optimize medication effectiveness and decrease the maintenance monitoring of the medication?
Safety If the two medications are similarly effective, but the medication with PGx information provides a reduction in serious adverse effects in the long term, are the reduced adverse effects enough to justify switching therapies?
Safety Does the medication that has a known PGx relationship narrow it to specific indications and does it require formulary restriction for the specified indications with prescribing limited to specialty clinicians?
Safety Are certain populations at risk for adverse effects?
Pharmacoeconomics Is the PGx therapy more cost-effective than conventional therapy for the short term or long term?

Source: Poppe LB, Roederer MW. Global formulary review: How do we integrate pharmacogenomic information? Published online, April 12, 2011. Abstract available here: http://www.theannals.com/cgi/content/abstract/aph.1P557v1. Permission to reprint is granted by the publisher.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.